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Introduction
　The p53 tumor suppressor gene and its downstream 
factors act as key regulators of inhibition of the G1 to S 
phase transition.  G1-S progression in the mammalian 
cell cycle is regulated by phosphorylation of Retinoblas-
toma（Rb）family proteins and subsequent release of 
E2F transcription factor1，2.  Cyclin-dependent kinases
（CDKs）-2, -4, and -6 are active on association with their 
catalytic partner, cyclin D or E, and are responsible for 
hyperphosphorylation of Rb1，2.  The kinase activity of 
CDKs is negatively regulated by a series of CDK 
inhibitors（CKIs） : the CIP/KIP family（p21, p27, and 
p57）and INK4 family（p16, p15, p18, and p19） 3.  p21, 
the first CKI to be identified and characterized, was 
initially reported as the downstream effector of p53, 
and its overexpression results in cell cycle arrest4.
　Abnormalities in G1 phase cell cycle regulation have 
been implicated in the pathogenesis of several types of 
human malignancies.  p21 has been intensively studied 
for its contribution to tumor suppression.  Van Oijen et 
al.5 reported a strong negative correlation between the 
expression of p21 and the proliferative potential of head 
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Abstract: The environmental contaminant benzo ［a］ pyrene（B ［a］ P）has been regarded as one of the pathogens 
of oral premalignant and malignant lesions. To elucidate the pathogenesis of oral premalignancies, B ［a］ P-
induced dysplasia of the murine tongue was investigated for G1-associated cell cycle regulation.  B ［a］ P 
solution was applied orally up to six weeks to induce epithelial dysplasia of the tongue.  BrdU incorporation 
and the expression of p21, cyclin D1, and CDK4 were examined by immunohistochemistry and Western 
blotting.  Rb phosphorylation and E2F-Rb binding were examined by immunoprecipitation and Western 
blotting.  B ［a］ P treatment resulted in dysplastic changes and active DNA synthesis in the tongue epithelia.  
Immunohistochemical analyses showed p21 up-regulation and cyclin D1/CDK4 overexpression in B ［a］ P-
induced dysplasia.  Rb hyperphosphorylation and E2F release were caused by B ［a］ P treatment.  Thus, 
dysregulation of G1-phase regulation is likely to be an important event in the development of oral epithelial 
dysplasia in mice.
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and neck carcinoma cells.  Amplification, overexpres-
sion, and rearrangement of cyclin D1 gene are 
frequently observed in various malignant tumors 
including head and neck squamous cell carcinomas6. 
Also, studies on rodent models of experimental tumors 
revealed that cyclin D1 overexpression occurs in the 
two-stage chemical carcinogenesis of murine skin7. 
Transgenic overexpression of wild-type cyclin D1 gene 
resulted in abnormal proliferative responses of epider- 
mal keratinocytes in mice8.  Another report showed that 
a cyclin D1 conditional transgene with a keratin-5 
promoter and skin-specific overexpression enhanced the 
susceptibility of dimethylbenz ［a］ anthracene（DMBA）-
induced skin tumorigenesis9.  In contrast, mice deficient 
for cyclin D1 gene displayed a reduced incidence of v-Ha-
ras-dependent, DMBA-induced skin papilloma10.  These 
previous reports suggest that disruption of G1 phase 
regulation leads to unregulated growth and tumor 
promotion.  However, less is known about the changes 
in cell cycle regulation during the formation of 
epithelial dysplasia of the oral mucosa.
　Tobacco-associated polycyclic aromatic hydrocarbon 
benzo ［a］ pyrene（B ［a］ P）is an indirect carcinogen ubi- 
quitous in the environment11.  Its electroreactive 
metabolites act as strong mutagens in various organs 
by forming DNA adducts12―15.  Because this compound 
has been implicated in the etiology of malignant tumor 
formation in the respiratory and digestive tracts, 
intensive investigations have been done on B ［a］ P-
induced experimental carcinogenesis in the trachea16 
and stomach17.  Repeated oral application of B ［a］ P 
solutions efficiently produces tumors in the buccal 
pouch and tongue of rodents18，19.  Park et al. reported 
that chronic exposure to B ［a］ P resulted in malignant 
transformation of HPV16-immortalized human oral 
keratinocytes in vitro20.  Although many studies have 
been directed at the malignant transformation of B ［a］ P-
exposed tissue and cultured cells, the critical events 
that occur during the formation of oral epithelial 
dysplasia have not been examined yet.  For more 
sophisticated diagnosis and treatment of oral leuko-
plakia and other precancerous lesions, it is necessary 
to understand the pathogenic mechanisms of the 
dysplasia.
　In the current study, we focused on the possible 
alterations in the regulation of G1 to S phase cell cycle 
progression and analyzed the changes in the expression 
of G1-related regulators on a mouse model of B ［a］ P-
induced oral epithelial dysplasia.
Materials and methods
1．Animals and carcinogen treatment
　C57BL6J mice were purchased from Sankyo Labo- 
ratory Service（Tokyo, Japan） .  Animals were bred in 
specific pathogen-free conditions and used for experi-
ments between 6 and 12 weeks of age.  Mice were 
divided into two groups（five mice for each treatment 
period）and control（five mice） .  Twenty μ l of tricaprylin
（for control）or an equal volume of 1.0％（w/v）B ［a］ P
（Sigma, St Louis, MO）in tricaprylin（for experimental）
was administered per os daily for one to six weeks. 
Mice were then euthanized by CO2 inhalation and the 
tongue tissue was immediately resected.  For im- 
munoprecipitation and Western blotting, the resected 
tissue was snap-frozen in liquid nitrogen and stored at 
－ 80℃ until use.  For histology, the resected tissue was 
immediately fixed in 10％ neutral-buffered formalin 
and embedded in paraffin.
2．Antibodies（Abs）
　Rabbit anti-mouse p16, p27, Rb, cyclin E, CDK2, and 
CDK4 polyclonal Abs（immunoglobulin（Ig）G） , mouse 
anti-mouse E2F-1（IgG2a） , cyclin D1（IgG1） , and p21
（IgG1）monoclonal Abs were purchased from Santa 
Cruz Biochemistry（San Diego, CA） .  Mouse monoclonal 
anti-mouse p21 Ab（IgG1）was purchased from Phar- 
mingen（San Diego, CA） .  Biotinylated anti-BrdU Ab 
was purchased from Medical and Biological Laborato-
ries（Nagoya, Japan） .
3．5-bromodeoxyuridine（BrdU）incorporation
　Mice were injected i.p. with BrdU（100 mg/kg body 
weight in 200 μ l PBS）16 h before euthanization. 
Serial sections of tongue tissue were deparaffinized, 
and incubated in 2 M HCl for 30 minutes at 37℃. 
Endogenous peroxidase was reduced by preincubating 
with 0.3％ H2O2.  The sections were then trypsinized 
and stained with biotinylated anti-BrdU Ab followed by 
peroxidase-conjugated streptavidin.  Immune com-
plexes were detected with diaminobenzidine. 
4．Immunohistochemistry
　Serial sections of 4- μ m thickness were prepared and 
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deparaffinized with xylene and ethanol. Immunohisto-
chemical staining was performed with a Histofine® SAB-
PO kit（Nichirei, Tokyo, Japan）according to the 
manufacturer's instructions. Briefly, sections were 
quenched with 0.3％ H2O2 to reduce intrinsic peroxidase 
activity and blocked with 10％ normal goat serum. 
Sections were incubated for 2 h at room temperature in 
a humidified chamber with primary Abs or their isotype-
matched control Ig.  After incubating with biotin-
conjugated second anti-IgG for 30 min at room 
temperature, peroxidase-conjugated streptavidin solu-
tion was applied to all sections for 30 min.  Immune 
complexes were detected with DAB.
5．Immunoprecipitation
　Cell lysate was precleared with normal mouse serum 
and Protein G Sepharose beads（Amersham Pharmacia 
Biotech, Uppsala, Sweden） .  Precleared lysate was 
incubated with Protein G Sepharose beads conjugated 
with primary Ab. After 2-h incubation at 4℃ under 
constant agitation, the beads were washed in lysis 
buffer and boiled for 10 min in 2x SDS loading buffer
（0.1 M Tris-HCl, pH 6.8, 4％ SDS, 20％ glycerol, 0.1％ 
mercaptoethanol, 0.004％ bromophenol blue）to elute 
the conjugated protein.  The supernatant was separated 
by SDS-PAGE and subjected to subsequent Western 
immunoblotting.
6．Western blotting
　The frozen samples were homogenized and protein 
was solubilized in 0.25％ IGEPAL lysis buffer（20 mM 
HEPES pH 7.5, 350 mM NaCl, 25％ glycerol, 0.25％ 
IGEPAL CA-630, 1 mM sodium o-vanadate）supple-
mented with a Complete MiniTM Protease Inhibitor 
Tablet（Roche Diagnostics, Mannheim, Germany） .  The 
cell lysate was clarified by centrifugation, and protein 
was separated by SDS-PAGE and transferred to a 
HybondTM PVDF membrane（Amersham Pharmacia） . 
The membrane was blocked with skim milk and reacted 
with primary Ab for 90 min at room temperature. 
The membrane was then washed and reacted with 
HRP-conjugated secondary Ab.  Protein bands were 
visualized with an ECLTM Western blot detection system
（Amersham Pharmacia） .
 
Results
1．Histological changes in murine tongue epithe-
lia induced by B ［a］ P treatment
　Observation of the excised tongue under dissection 
microscope showed that B ［a］ P did not induce tumor 
formation in the tongue within six weeks.  Fig. 1 shows 
hematoxylin-eosin（HE）-stained sections of the tongue 
tissue from normal（Fig. 1a）and B ［a］ P-treated（Fig. 
1b-d）mice.  One-week treatment with B ［a］ P was 
insufficient to induce any marked changes in the tongue 
epithelium（Fig. 1b） .  However, mild to moderate 
dysplastic changes of the tongue epithelium occurred 
after three-week treatment（Fig. 1c） .  Morphological 
alterations such as loss of polarity of the basal cells, 
basaloid appearance of the suprabasal cells, increased 
nucleus/ cytoplasm ratio and enlarged nucleoli of 
the prickle cells, cytoplasmic hyperchromatism, and 
thickening of the keratinized layers were seen in 
epithelia from mice treated with B ［a］ P.  These features 
were more remarkably observed in the tissue from the 
six-week-treated mice（Fig. 1d）An increase in mitotic 
figures or nonphysiologic mitoses was not seen at any 
time（Fig. 1b-d） .
2．BrdU incorporation in tongue epithelial cells 
treated with B ［a］ P
　We next carried out in vivo BrdU incorporation 
experiments to evaluate the DNA synthesizing activity 
of B ［a］ P-exposed cells.  Basal cells of the untreated 
normal epithelium were weakly positive for BrdU 
staining ; only a very small number of suprabasal cells 
were BrdU-positive（Fig. 2a） .  B ［a］ P treatment 
remarkably increased BrdU incorporation in basal and 
suprabasal cells within one week（Fig. 2b） .  Strong 
positive staining for BrdU was noted in the majority of 
prickle cells in the epithelia treated with B ［a］ P for 
three（Fig. 2c）and six weeks（Fig. 2d） .
3．Changes in the expression of p21 in tongue 
epithelium induced by B ［a］ P
　We next examined whether the genotoxic stresses due 
to B ［a］ P treatment activate the p21-dependent cell 
cycle regulation cascade.  A small number of cells in the 
normal tongue were found to be weakly positive for p21
（Fig. 3a） .  After a six-week treatment with B ［a］ P, this 
CKI was markedly induced in the epithelia, especially 
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Fig. 2　Incorporation of BrdU in normal and B ［a］ P-treated tongue epithelia.
Mice were treated by the oral application of tricaprylin（a）or a 0.1％ w/v 
tricaprylin solution of B ［a］ P for one（b） , three（c） , or six（d）weeks, and BrdU 
was injected i.p. 16 h before euthanization. BrdU incorporation in all the layers of 
the epithelium of the tongue was examined by anti-BrdU immunohistochemical 
staining.（Bars, 30μ m） 
Fig. 1　Epithelial dysplasia of murine tongue mucosa induced by B ［a］ P. 
Mice were treated by the oral application of tricaprylin（a）or a 0.1％ w/v 
tricaprylin solution of B ［a］ P for one（b） , three（c） , or six（d）weeks. Mice were 
euthanized and sections of the tongue were stained with HE.（Bars, 30μ m） 
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Fig. 4　Western blot analysis of p21 expression in B ［a］ P-treated tongue tissue. 
Mice were treated by the oral application of tricaprylin or tricaprylin solution of 
B ［a］ P for one to six weeks. Expression of p21 was analyzed by Western blotting as 
described in Materials and Methods. Lane 1: tricaprylin-treated control. Lanes 2, 
3, and 4 : treated with B ［a］ P for one, three, and six weeks, respectively. 
Representative data from three individual experiments are shown.
Fig. 5　Expression of cyclin D and CDK4 in B ［a］ P-treated tongue tissue.
Mice were treated with tricaprylin（a, c）or a tricaprylin solution of B ［a］ P for six 
weeks（b, d） . Cyclin D and CDK4 were detected by immunohistochemistry. 
Representative data from three individual experiments are shown.（Bars, 60μ m） 
Fig. 3　Distribution of p21 protein in B ［a］ P-treated tongue epithelia.
Mice were treated with tricaprylin（a）or a tricaprylin solution of B ［a］ P for 
six weeks（b） . p21 protein in the tongue epithelium was detected by 
immunohistochemistry.（Bars, 60μ m） 
in the basal cell layer（Fig. 3b） .  Similar results 
were obtained from Western blot analysis（Fig. 4） . 
Constitutive p21 expression was also detected in the 
immunoblot assay.  B ［a］ P treatment up-regulated the 
expression of p21 in the tongue tissue.  These results 
suggested that B ［a］ P might induce the p21-dependent 
inhibition of cell cycle progression.  Expression of 
CKIs p16, p27, and p57 was also examined by 
immunohistochemistry and Western immunoblotting, 
but no detectable changes were observed（data not 
shown） .
4．Changes in the expression of cyclin D1 and 
CDK4 induced by B ［a］ P
　Immunohistochemical staining showed that cyclin 
D1 immunoreactivity was almost undetectable in 
untreated normal epithelium（Fig. 5a） .  Only a small 
number of basal cells were weakly positive for cyclin 
D1.  On the other hand, positive cyclin D1 staining was 
observed in the basal cell layer of six-week-treated 
epithelium（Fig. 5b） .  Cyclin D1 was also detected in 
some of the suprabasal cells, but the prickle cells were 
negative for this protein.  The expression of this protein 
was time-dependently augmented by the treatment
（data not shown） .  Similar results were obtained from 
the immunohistochemistry for CDK4（Fig. 5c and d） .
　Western immunoblot assay was also performed to 
examine the expression of cyclin E/CDK2, but marked 
changes were not induced by B ［a］ P treatment（data not 
shown） .
5．Hyperphosphorylation of Rb and release of 
E2F in B ［a］ P-treated tongue epithelium
　For the next set of experiments, Western blot analysis 
was performed to examine the phosphorylation status 
of Rb.  Using a primary antibody which recognizes both 
hyperphosphorylated（ppRb）and hypophosphorylated
（pRb）forms of the protein, Rb appears as two distinct 
bands: higher molecular weight ppRb and lower 
molecular weight pRb.  pRb was dominant in the 
control tissue（Fig. 6; lane 1） , but ppRb was remarkably 
increased by B ［a］ P in a time-dependent manner.  These 
data suggested that the phosphorylation level of Rb was 
elevated in B ［a］ P-induced epithelial dysplasia.
　Next, the association of Rb and E2F in the untreated 
and B ［a］ P-treated tissues was examined by immuno-
precipitation and subsequent Western immunoblotting
（Fig. 7） .  A distinct Rb band was observed in the sample 
from untreated tissue（Fig. 7; lane 1） .  Exposure to 
B ［a］ P resulted in a marked time-dependent decrease in 
the Rb band intensity（Fig. 7; lanes 2-4） , suggesting 
that E2F release from Rb was notably enhanced in 
B ［a］ P-induced epithelial dysplasia through Rb hyper- 
phosphorylation.
Discussion
　B ［a］ P is a widespread and persistent pollutant 
contained in tobacco smoke and some types of food11. 
This compound itself is non-genotoxic, but its meta- 
bolite B ［a］ P diol epoxide（BPDE）acts as a strong 
mutagen12―15.  These metabolically-activated mutagens 
react with DNA to form BPDEs-DNA adducts, resulting 
in DNA mis-replication at the affected sites21.  When 
the DNA lesions are formed at the critical sites for 
tumor suppression or oncogenesis and fail to be 
properly and promptly repaired, the cells are directed to 
the premalignant condition, and then to malignant 
transformation.  In the current study, changes in cell 
cycle regulation during the development of epithelial 
dysplasia were investigated using a murine model of 
B ［a］ P-induced oral epithelial dysplasia.  B ［a］ P dis- 
solved in tricaprylin was orally applied, and mild to 
moderate dysplastic changes of the epithelia were 
successfully induced within six weeks after the start of 
the B ［a］ P treatment.  Findings from histological 
analyses of B ［a］ P-treated tongue epithelium（Fig. 1）
suggested that the differentiation/proliferation proper-
ties of the epithelial cells were altered by chronic 
exposure to this DNA damaging agent. Increases in 
mitotic figures or development of carcinoma in situ 
were not seen in these experiments.  Oral mucosal 
tissue from all B ［a］ P-treated animals appeared macro- 
scopically normal.  Some of the mice in the experi- 
mental group died probably due to drug-induced liver 
dysfunction before oral tumors could develop.  To 
observe cancer development in the murine system, an 
extended treatment period with lower carcinogen 
concentration or multistep induction of carcinogenesis 
with other mutagens might be required.  We also used 
another genotoxic chemical, 4-nitroquinoline-n-oxide（4-
NQO） , which has been widely used for rat models of 
oral carcinogenesis, but oral mucosa of C57BL6 mice 
appeared to be more sensitive to B ［a］ P than to 4-NQO 
in terms of the susceptibility of epithelial dysplasia
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（data not shown） .
　The data from immunohistochemical staining and 
immunoblots for p21 demonstrated that B ［a］ P ex- 
posure augmented the expression of this protein, 
especially in the basal cell layers.  Once genomic DNA is 
damaged, induced and activated p21 disturbs the entry 
into S phase, providing a chance to repair DNA lesions. 
The augmented expression of p21 noted in our data 
could be regarded as a defensive reaction against B ［a］ P 
toxicity.  Expression of its upstream regulator p53 was 
not affected by B ［a］ P（data not shown） , corresponding 
with previous reports that B ［a］ P activates the p53-
independent cell cycle-arresting cascade in vitro21，22. 
B ［a］ P might activate the p21-dependent/p53-independ-
ent pathway of growth suppression during the G1 phase.
　In spite of p21 induction, enhanced incorporation of 
BrdU indicated up-regulated DNA synthesizing activity 
in B ［a］ P-treated epithelial cells. Some of the sup- 
rabasal cells turned BrdU-positive after B ［a］ P ex- 
posure, suggesting that the cells sustained their growth 
activity instead of going to the physiological differentia-
tion.  p21 was up-regulated by the mitogenic stimuli as 
a physiological negative-feedback reaction to block 
nonphysiological acceleration of the cell cycle.  We 
speculate that the B ［a］ P-induced S-phase promoting 
forces overcame the blockade by p21.  Overproduced 
p21 protein might be consumed by binding the 
overproduced cyclin D1/CDKs complexes.  Inhibition of 
cyclin E/CDK2 by p21 might be thus unsuccessful, 
resulting in the S-phase entry of the cells.
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Fig. 6　Phosphorylation status of Rb protein in B ［a］ P-treated murine tongue. 
Mice were treated with tricaprylin or B ［a］ P in tricaprylin for one to six weeks. 
Resected tongue was homogenized, and protein was solubilized by lysis buffer. 
Expression of Rb was analyzed by Western blotting. Rb was detected as two 
distinct bands; the hyperphosphorylated form（ppRb）with a slower migration rate 
and the hypophosphorylated form with higher migration rate（pRb） . Lane 1: 
tricaprylin-treated control. Lanes 2, 3, and 4: treated with B ［a］ P for one, three, 
and six weeks, respectively. Representative data from three individual 
experiments are shown. 
Fig. 7　Effect of B ［a］ P on the binding of Rb and E2F in murine tongue. 
Mice were treated by oral application of tricaprylin or a tricaprylin solution 
of B ［a］ P for one to six weeks. Lysate of the resected tongue tissue was 
immunoprecipitated（IP）with Protein G Sepharose and anti-E2F monoclonal 
antibody. The E2F immunoprecipitate was separated by SDS-PAGE and 
immunoblotted（IB）with anti-E2F（upper panel）and Rb（lower panel）
monoclonal antibodies. Lane 1: tricaprylin-treated control. Lanes 2, 3, and 4: 
treated with B ［a］ P for one, three, and six weeks, respectively. 
Representative data from three individual experiments are shown.
　Expression of cyclin D1 and CDK4, the targets of p21, 
was examined to investigate whether these factors are 
induced to overcome the p21 blockade, because cyclin 
D up-regulation has been reported to be associated 
with malignancies6―8.  Immunohistochemical staining 
showed that cyclin D1 and CDK4 were markedly up-
regulated in response to B ［a］ P treatment at the sites 
where p21 overexpression was observed.  These data on 
cyclin D1 correspond to previous reports on the 
precancerous lesions of human oral and laryngeal 
mucosa23―25.  We have no direct evidence that the cyclin 
D1/CDK4 complex is enzymatically activated as well as 
overexpressed.  A kinase assay of purified protein is 
needed to confirm this. However, the cyclin D1/CDK4 
substrate Rb was found to be time-dependently 
hyperphosphorylated（Fig. 6）and release of E2F 
transcription factor from Rb occurred after B ［a］ P 
treatment（Fig. 7） , suggesting that the p21-dependent 
pathway of cell cycle arrest did not properly work to 
block G1-S progression.
　Our results indicated that BrdU-positive cells were 
distributed mainly in the suprabasal and prickle cell 
layers（Fig. 2） , not in the basal layers where cyclin 
D1/CDK4 was overexpressed（Fig. 5） .  The cyclin 
D1/CDK4 complex works in the early stage of the G1 
phase for the progression to the late G1 phase.  In the 
late G1, cyclin E/CDK2 promotes S-phase entry instead 
of cyclin D/CDK4.  Our preliminary data showed 
that B ［a］ P treatment up-regulated cyclin E in the 
suprabasal and prickle cells（data not shown） .  We 
speculate that B ［a］ P accelerates cell cycle progression 
of the basal cells through an overexpression of the early 
G1 proteins, resulting in the increase and accumulation 
of the S-phase cells in the suprabasal and prickle cell 
layers.
　It is likely that B ［a］ P-exposed epithelial cells are 
escaping from a physiologically-stable condition and 
entering the actively proliferating stages. In in vitro 
cultured cells, B ［a］ P transiently induces cell cycle 
arrest. Guo et al.21 demonstrated that the cell cycle of 
Swiss 3T3 cells was first arrested by B ［a］ P and 
mitogenic stimuli, and then recovered from arrest and 
progressed to the G2/M phases.  They also noted that 
the quantified level of DNA damage did not decline 
during recovery from the arrest and re-entry into cell 
cycle progression, and mentioned the existence of a cell 
cycle checkpoint adaptation mechanism.  Additionally, 
Khan et al.26 reported that S phase re-entry occurs 
when G1-arrested human MCF-7 cells are treated with 
the B ［a］ P metabolite BPDE.  We did not perform any 
detailed investigation to examine the very early events 
induced by B ［a］ P treatment.  However, it is speculated 
that there is a similar checkpoint adaptation during the 
development of experimental epithelial dysplasia.
　Overall, our current study demonstrates an associa-
tion between dysplastic changes of the oral mucosal 
epithelia and alterations in G1 cell cycle control in the 
mouse.  The data suggest that continuous carcinogen 
exposure leads cells to the active proliferation stages in 
vivo.  We failed to detect changes in the gene expression 
of some cell cycle regulatory factors including CKIs 
other than p21.  This is probably because such changes 
are too small to detect or occur mainly in very restricted 
numbers of epithelial cells. More sophisticated 
experimental techniques such as laser micro-dissection 
will help to solve these problems.  The checkpoint 
adaptation mechanism should be elucidated in future 
studies for the further understanding of oral epithelial 
carcinogenesis. 
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